BioTuesdays

Tag - PSTV

Plus Therapeutics Logo

Maxim starts Plus Therapeutics at buy; PT $6

Maxim Group launched coverage of Plus Therapeutics (NASDAQ:PSTV) with a “buy” rating and price target of $6. The stock closed at $2.56 on Oct. 15. The company’s lead asset, rhenium nanoliposome (RNL), is being developed...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.